WilliamTeo
2021-08-10
Pro
Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠疫苗可能比辉瑞更好对抗德尔塔变异毒株；突破性案例随着时间的推移而增加</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":896406617,"tweetId":"896406617","gmtCreate":1628598943439,"gmtModify":1631892264519,"author":{"id":3575416215572570,"idStr":"3575416215572570","authorId":3575416215572570,"authorIdStr":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pro</p></body></html>","htmlText":"<html><head></head><body><p>Pro</p></body></html>","text":"Pro","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/896406617","repostId":1122891084,"repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://www.laohu8.com/m/news/1122891084?lang=zh_CN&edition=full","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠疫苗可能比辉瑞更好对抗德尔塔变异毒株；突破性案例随着时间的推移而增加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<p><ul> <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s against the Delta variant of the coronavirus, <i>Reuters reports</i>.</li> <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li> <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li> <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li> <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li> <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li> <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li> <li>In a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li> <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li> <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li> <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li> <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li> <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li> <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">莫德纳公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项尚未经过同行评审的研究包括了梅奥诊所卫生系统的50,000多名患者。</li><li>研究人员发现，Moderna的Covid-19疫苗的效力从2021年初的86%降至7月份（当时德尔塔变异毒株占主导地位）的76%。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在预防Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要进行Moderna加强注射。</li><li>在另一项研究中，安大略省的老年疗养院居民在注射Moderna疫苗后产生了比辉瑞/BioNTech疫苗后更强的免疫反应——特别是针对变异体。</li><li>辉瑞发言人表示：“我们仍然认为……在全面接种疫苗后的6至12个月内，可能需要第三剂加强剂，以保持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性新冠肺炎的几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，该研究包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测呈阳性的几率较高。</li><li>在60岁以上的患者中，自第二次注射后146天，检测呈阳性的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”以色列Leumit Health Services的合著者Eugene Merzon博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠疫苗可能比辉瑞更好对抗德尔塔变异毒株；突破性案例随着时间的推移而增加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time<blockquote>Moderna新冠疫苗可能比辉瑞更好对抗德尔塔变异毒株；突破性案例随着时间的推移而增加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-10 16:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul> <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s against the Delta variant of the coronavirus, <i>Reuters reports</i>.</li> <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li> <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li> <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li> <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li> <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li> <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li> <li>In a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li> <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li> <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li> <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li> <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li> <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li> <li>Israel has already started administering booster shots to people over the age of 60.</li> </ul></p><p><blockquote><ul><li>根据medRxiv发表的两份报告，由<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>可能不如<a href=\"https://laohu8.com/S/MRNA\">莫德纳公司。</a>对抗冠状病毒的德尔塔变异毒株，<i>路透社报道</i>.</li><li>这项尚未经过同行评审的研究包括了梅奥诊所卫生系统的50,000多名患者。</li><li>研究人员发现，Moderna的Covid-19疫苗的效力从2021年初的86%降至7月份（当时德尔塔变异毒株占主导地位）的76%。</li><li>然而，在同一时期，辉瑞/BioNTech疫苗的有效性从76%下降到42%。</li><li>领导梅奥研究的马萨诸塞州数据分析公司的Venky Soundararajan博士说，虽然这两种疫苗在预防Covid住院方面仍然有效，但对于今年早些时候接种辉瑞或Moderna疫苗的人来说，可能很快就需要进行Moderna加强注射。</li><li>在另一项研究中，安大略省的老年疗养院居民在注射Moderna疫苗后产生了比辉瑞/BioNTech疫苗后更强的免疫反应——特别是针对变异体。</li><li>辉瑞发言人表示：“我们仍然认为……在全面接种疫苗后的6至12个月内，可能需要第三剂加强剂，以保持最高水平的保护。”</li><li>在medRxiv上发布的一项研究中，观察到接种疫苗几个月后，突破性新冠肺炎的几率会上升。</li><li>数据表明，五个月或更长时间前接种第二剂辉瑞/BioNTech疫苗的人比不到五个月前完全接种疫苗的人更有可能检测出新冠肺炎阳性。</li><li>总体而言，在一项研究中，1.8%的人检测呈阳性，该研究包括以色列近34,000名完全接种疫苗的成年人，他们接受了检测，看看他们是否有突破性的新冠肺炎病例。</li><li>在所有年龄段，当最后一剂疫苗至少提前146天接种时，检测呈阳性的几率较高。</li><li>在60岁以上的患者中，自第二次注射后146天，检测呈阳性的几率几乎高出三倍。</li><li>他补充说：“很少有患者需要住院治疗，现在从住院、机械通气需求或死亡率方面评估这些新感染的严重程度还为时过早。”“我们计划继续我们的研究，”以色列Leumit Health Services的合著者Eugene Merzon博士说。</li><li>以色列已经开始对60岁以上的人进行加强注射。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3134,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/896406617"}
精彩评论